CorMedix to acquire substantially all Heron Therapeutics assets, adding four FDA-approved brands including ZYNRELEF

CorMedix Inc.

CorMedix entered a definitive asset purchase agreement to buy substantially all of Heron Therapeutics' assets; deal announced November 9, 2026, with a Pharmakon term loan facility involved in funding.
Consideration includes CorMedix common stock issued to Heron in a private placement; Heron stockholders must vote on the transaction; earn-out milestones and royalty payments are contemplated.
Acquired portfolio is described as four FDA-approved commercial brands, including ZYNRELEF, expected to diversify revenue and be accretive to earnings.
Closing conditioned on Heron stockholder approval and required regulatory clearances; the agreement includes a termination fee payable by Heron in specified circumstances.
No purchase price, per-share value or premium is disclosed in the filed text; continued separate payment for ZYNRELEF under the NOPAIN Act is cited as a revenue driver.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.